English

OSIRIS THERAPEUTICS, INC.

EDGAR

Annual report (10-K) · filed 2019-03-15

53 filing records in this dataset, filed from 2006-09-15 to 2019-03-15. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

40.8 million Unit12

2018 Q4 · Unit12

Exact inputs and evidence

Revenue: 142824000 Unit12 Source
Revenue: 102001000 Unit12 Source

Operating margin

15.26%

2018 Q4 · %

Exact inputs and evidence

Operating Income: 9853000 Unit12 Source
Operating Income: 3625000 Unit12 Source
Revenue: 142824000 Unit12 Source
Revenue: 102001000 Unit12 Source

Operating cash flow

-5.72 million Unit12

2018 Q4 · Unit12

Exact inputs and evidence

Operating Cash Flow: 7304000 Unit12 Source
Operating Cash Flow: 13020000 Unit12 Source

Free cash flow

-5.77 million Unit12

2018 Q4 · Unit12

Exact inputs and evidence

Operating Cash Flow: 7304000 Unit12 Source
Operating Cash Flow: 13020000 Unit12 Source
Capital Expenditure: 242000 Unit12 Source
Capital Expenditure: 187000 Unit12 Source

Cash and cash equivalents: 16.4 million Unit12 2018-12-31 Source
Exact value

16367000 Unit12
Long-term debt including current maturities: Not available
Shares outstanding: 34.5 million Unit1 2018-12-31 Source
Exact value

34527000 Unit1

Reported share-count change

0.00% · 1 thousand Unit1

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

34526000 Unit1 · 2017-12-31· Source
34527000 Unit1 · 2018-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

14.3 million USD

2010-10-01 – 2011-09-30

Exact inputs and evidence

Net income: 13125000 USD · 2010-01-01 – 2010-12-31 Source
Net income: 8711000 USD · 2010-01-01 – 2010-09-30 Source
Net income: 4039000 USD · 2011-01-01 – 2011-03-31 Source
Net income: 1792000 USD · 2011-04-01 – 2011-06-30 Source
Net income: 4013000 USD · 2011-07-01 – 2011-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2019-03-15.

Financial data available through: 2018-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2018-12-31
Operating income: 7 of 11 periods available· newest 2018-12-31
Net income: 3 of 11 periods available· newest 2010-12-31
Operating cash flow: 7 of 11 periods available· newest 2018-12-31
Capital expenditure: 7 of 11 periods available· newest 2018-12-31
Total assets: 2 of 11 periods available· newest 2018-12-31
Total liabilities: 2 of 11 periods available· newest 2018-12-31
Current assets: 2 of 11 periods available· newest 2018-12-31
Current liabilities: 2 of 11 periods available· newest 2018-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2018-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2018-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+20.5%

Prior period

Unit12 118.51 million

2017-01-01 – 2017-12-31
Current period

Unit12 142.82 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

142824000 − 118514000 = 24310000 Unit12

118514000 Unit12 · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
142824000 Unit12 · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · OSIRIS THERAPEUTICS, INC. · 2018-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Year-over-year change in Revenue: 24310000 Unit12 Concept: fundies:Revenue Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 142824000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1128412 Filing: 000155837019002094 Input fundies:Revenue: 118514000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1126956 Filing: 000155837019002094
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit12 12.53 million

Prior period

−Unit12 5.22 million

2017-01-01 – 2017-12-31
Current period

Unit12 7.3 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

7304000 − -5223000 = 12527000 Unit12

-5223000 Unit12 · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
7304000 Unit12 · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · OSIRIS THERAPEUTICS, INC. · 2018-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Year-over-year change in Operating cash flow: 12527000 Unit12 Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 7304000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1024466 Filing: 000155837019002094 Input fundies:OperatingCashFlow: -5223000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1024274 Filing: 000155837019002094
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-87.9%

Prior period

Unit12 2.01 million

2017-01-01 – 2017-12-31
Current period

Unit12 242,000

2018-01-01 – 2018-12-31

Exact inputs and evidence

242000 − 2008000 = -1766000 Unit12

2008000 Unit12 · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
242000 Unit12 · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · OSIRIS THERAPEUTICS, INC. · 2018-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Year-over-year change in Capital expenditure: -1766000 Unit12 Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 242000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1039483 Filing: 000155837019002094 Input fundies:CapitalExpenditure: 2008000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1039292 Filing: 000155837019002094
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2018-01-01 – 2018-12-31

Revenue Unit12 142.82 million 100% of revenue
Cost of revenue Unit12 38.14 million 27% of revenue
Operating expenses Unit12 94.83 million 66% of revenue
Operating income Unit12 9.85 million 6.9% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow Unit12 7.3 million 5.1% of revenue
Capital expenditure Unit12 242,000 0.2% of revenue
Free cash flow Derived Unit12 7.06 million 4.9% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	118514000	120503000 Derived	-1989000	Unavailable	Unavailable	-7231000 Derived	Source 2017-01-01 – 2017-12-31: 118514000 Unit12 Inspect Revenue Open source 2017-01-01 – 2017-12-31: -1989000 Unit12 Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -5223000 Unit12 Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 2008000 Unit12 Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	142824000	132971000 Derived	9853000	Unavailable	Unavailable	7062000 Derived	Source 2018-01-01 – 2018-12-31: 142824000 Unit12 Inspect Revenue Open source 2018-01-01 – 2018-12-31: 9853000 Unit12 Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 7304000 Unit12 Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 242000 Unit12 Inspect Capital Expenditure Open source

Amounts are exact, in Unit12.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit12 142.8M 2018

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit12)	Source evidence
20172017-12-31	Revenue	118514000	Revenue: 118514000 Open source
20182018-12-31	Revenue	142824000	Revenue: 142824000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

20.5% 2018

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 118514000 Open source
20182018-12-31	Year over year	20.5%	Revenue: 142824000 Open source Revenue: 118514000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 6.9% 2018

Free cash flow margin 4.9% 2018

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	-1.7%	Operating Income: -1989000 Open source Revenue: 118514000 Open source
20182018-12-31	Operating margin	6.9%	Operating Income: 9853000 Open source Revenue: 142824000 Open source
2017-12-31	Net margin	Not reported	Revenue: 118514000 Open source
2018-12-31	Net margin	Not reported	Revenue: 142824000 Open source
20172017-12-31	Free cash flow margin	-6.1%	Revenue: 118514000 Open source Operating Cash Flow: -5223000 Open source Capital Expenditure: 2008000 Open source
20182018-12-31	Free cash flow margin	4.9%	Revenue: 142824000 Open source Operating Cash Flow: 7304000 Open source Capital Expenditure: 242000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit12 7.3M 2018

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20172017-12-31	Operating cash flow	-5223000	Operating Cash Flow: -5223000 Open source
20182018-12-31	Operating cash flow	7304000	Operating Cash Flow: 7304000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit12 7.1M 2018

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20172017-12-31	Free cash flow	-7231000	Operating Cash Flow: -5223000 Open source Capital Expenditure: 2008000 Open source
20182018-12-31	Free cash flow	7062000	Operating Cash Flow: 7304000 Open source Capital Expenditure: 242000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

22.6% 2018

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Liabilities / assets	47%	Total Liabilities: 36728000 Open source Total Assets: 78122000 Open source
20182018-12-31	Liabilities / assets	22.6%	Total Liabilities: 22974000 Open source Total Assets: 101502000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.41× 2018

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Current assets / current liabilities	2.08×	Current Assets: 72927000 Open source Current Liabilities: 35102000 Open source
20182018-12-31	Current assets / current liabilities	3.41×	Current Assets: 70247000 Open source Current Liabilities: 20592000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	Unavailable Not reported for this period.	−Unit12 13.27 million Exact value Exact value: -13271000 Unit12 2012-01-01 – 2012-12-31: -13271000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OSIRIS THERAPEUTICS, INC. · 2012-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Operating Cash Flow: -13271000 Unit12 Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -13271000 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5337794 Filing: 000110465917019408 The citation records this snapshot. The page link may show a newer release later.	Unit12 128,000 Exact value Exact value: 128000 Unit12 2012-01-01 – 2012-12-31: 128000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OSIRIS THERAPEUTICS, INC. · 2012-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Capital Expenditure: 128000 Unit12 Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 128000 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5427995 Filing: 000110465917019408 The citation records this snapshot. The page link may show a newer release later.	−Unit12 13.4 million Calculation and evidence -13271000 − 128000 Unit12 Exact free cash flow: -13399000 Unit12 2012-01-01 – 2012-12-31: -13271000 Unit12 · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 128000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OSIRIS THERAPEUTICS, INC. · 2012-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Free cash flow: -13399000 Unit12 Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13271000 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5337794 Filing: 000110465917019408 Input fundies:CapitalExpenditure: 128000 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5427995 Filing: 000110465917019408 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	Unavailable Not reported for this period.	−Unit12 13.6 million Exact value Exact value: -13601000 Unit12 2013-01-01 – 2013-12-31: -13601000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OSIRIS THERAPEUTICS, INC. · 2013-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Operating Cash Flow: -13601000 Unit12 Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -13601000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5338251 Filing: 000110465917019408 The citation records this snapshot. The page link may show a newer release later.	Unit12 528,000 Exact value Exact value: 528000 Unit12 2013-01-01 – 2013-12-31: 528000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OSIRIS THERAPEUTICS, INC. · 2013-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Capital Expenditure: 528000 Unit12 Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 528000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5428446 Filing: 000110465917019408 The citation records this snapshot. The page link may show a newer release later.	−Unit12 14.13 million Calculation and evidence -13601000 − 528000 Unit12 Exact free cash flow: -14129000 Unit12 2013-01-01 – 2013-12-31: -13601000 Unit12 · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 528000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OSIRIS THERAPEUTICS, INC. · 2013-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Free cash flow: -14129000 Unit12 Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13601000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5338251 Filing: 000110465917019408 Input fundies:CapitalExpenditure: 528000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5428446 Filing: 000110465917019408 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	Unavailable Not reported for this period.	−Unit12 3.16 million Exact value Exact value: -3155000 Unit12 2014-01-01 – 2014-12-31: -3155000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OSIRIS THERAPEUTICS, INC. · 2014-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Operating Cash Flow: -3155000 Unit12 Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -3155000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5338965 Filing: 000110465917019408 The citation records this snapshot. The page link may show a newer release later.	Unit12 1.12 million Exact value Exact value: 1123000 Unit12 2014-01-01 – 2014-12-31: 1123000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OSIRIS THERAPEUTICS, INC. · 2014-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Capital Expenditure: 1123000 Unit12 Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 1123000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5428897 Filing: 000110465917019408 The citation records this snapshot. The page link may show a newer release later.	−Unit12 4.28 million Calculation and evidence -3155000 − 1123000 Unit12 Exact free cash flow: -4278000 Unit12 2014-01-01 – 2014-12-31: -3155000 Unit12 · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 1123000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OSIRIS THERAPEUTICS, INC. · 2014-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Free cash flow: -4278000 Unit12 Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3155000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5338965 Filing: 000110465917019408 Input fundies:CapitalExpenditure: 1123000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000110465917019408/osir-20141231.xml#5428897 Filing: 000110465917019408 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	Unavailable Not reported for this period.	−Unit12 10.98 million Exact value Exact value: -10979000 Unit12 2015-01-01 – 2015-12-31: -10979000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OSIRIS THERAPEUTICS, INC. · 2015-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Operating Cash Flow: -10979000 Unit12 Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -10979000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000104746918002273/osir-20171231.xml#1785061 Filing: 000104746918002273 The citation records this snapshot. The page link may show a newer release later.	Unit12 927,000 Exact value Exact value: 927000 Unit12 2015-01-01 – 2015-12-31: 927000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OSIRIS THERAPEUTICS, INC. · 2015-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Capital Expenditure: 927000 Unit12 Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 927000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000104746918002273/osir-20171231.xml#1850035 Filing: 000104746918002273 The citation records this snapshot. The page link may show a newer release later.	−Unit12 11.91 million Calculation and evidence -10979000 − 927000 Unit12 Exact free cash flow: -11906000 Unit12 2015-01-01 – 2015-12-31: -10979000 Unit12 · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 927000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OSIRIS THERAPEUTICS, INC. · 2015-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Free cash flow: -11906000 Unit12 Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10979000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000104746918002273/osir-20171231.xml#1785061 Filing: 000104746918002273 Input fundies:CapitalExpenditure: 927000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000104746918002273/osir-20171231.xml#1850035 Filing: 000104746918002273 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	Unavailable Not reported for this period.	−Unit12 6.24 million Exact value Exact value: -6238000 Unit12 2016-01-01 – 2016-12-31: -6238000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OSIRIS THERAPEUTICS, INC. · 2016-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Operating Cash Flow: -6238000 Unit12 Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -6238000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000104746918002273/osir-20171231.xml#1785827 Filing: 000104746918002273 The citation records this snapshot. The page link may show a newer release later.	Unit12 1.35 million Exact value Exact value: 1350000 Unit12 2016-01-01 – 2016-12-31: 1350000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OSIRIS THERAPEUTICS, INC. · 2016-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Capital Expenditure: 1350000 Unit12 Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 1350000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000104746918002273/osir-20171231.xml#1850793 Filing: 000104746918002273 The citation records this snapshot. The page link may show a newer release later.	−Unit12 7.59 million Calculation and evidence -6238000 − 1350000 Unit12 Exact free cash flow: -7588000 Unit12 2016-01-01 – 2016-12-31: -6238000 Unit12 · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 1350000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OSIRIS THERAPEUTICS, INC. · 2016-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Free cash flow: -7588000 Unit12 Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6238000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000104746918002273/osir-20171231.xml#1785827 Filing: 000104746918002273 Input fundies:CapitalExpenditure: 1350000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000104746918002273/osir-20171231.xml#1850793 Filing: 000104746918002273 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	Unavailable Not reported for this period.	−Unit12 5.22 million Exact value Exact value: -5223000 Unit12 2017-01-01 – 2017-12-31: -5223000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OSIRIS THERAPEUTICS, INC. · 2017-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Operating Cash Flow: -5223000 Unit12 Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -5223000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1024274 Filing: 000155837019002094 The citation records this snapshot. The page link may show a newer release later.	Unit12 2.01 million Exact value Exact value: 2008000 Unit12 2017-01-01 – 2017-12-31: 2008000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OSIRIS THERAPEUTICS, INC. · 2017-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Capital Expenditure: 2008000 Unit12 Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 2008000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1039292 Filing: 000155837019002094 The citation records this snapshot. The page link may show a newer release later.	−Unit12 7.23 million Calculation and evidence -5223000 − 2008000 Unit12 Exact free cash flow: -7231000 Unit12 2017-01-01 – 2017-12-31: -5223000 Unit12 · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 2008000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OSIRIS THERAPEUTICS, INC. · 2017-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Free cash flow: -7231000 Unit12 Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5223000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1024274 Filing: 000155837019002094 Input fundies:CapitalExpenditure: 2008000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1039292 Filing: 000155837019002094 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	Unavailable Not reported for this period.	Unit12 7.3 million Exact value Exact value: 7304000 Unit12 2018-01-01 – 2018-12-31: 7304000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OSIRIS THERAPEUTICS, INC. · 2018-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Operating Cash Flow: 7304000 Unit12 Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: 7304000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1024466 Filing: 000155837019002094 The citation records this snapshot. The page link may show a newer release later.	Unit12 242,000 Exact value Exact value: 242000 Unit12 2018-01-01 – 2018-12-31: 242000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OSIRIS THERAPEUTICS, INC. · 2018-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Capital Expenditure: 242000 Unit12 Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 242000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1039483 Filing: 000155837019002094 The citation records this snapshot. The page link may show a newer release later.	Unit12 7.06 million Calculation and evidence 7304000 − 242000 Unit12 Exact free cash flow: 7062000 Unit12 2018-01-01 – 2018-12-31: 7304000 Unit12 · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 242000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OSIRIS THERAPEUTICS, INC. · 2018-12-31 OSIRIS THERAPEUTICS, INC. (edgar:1360886) Free cash flow: 7062000 Unit12 Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:44:48Z Snapshot: 1b2141147461f48229047b124f0642e02ad35b8e3310f5030123d604e5f8d762 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1360886?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 7304000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1024466 Filing: 000155837019002094 Input fundies:CapitalExpenditure: 242000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1360886/000155837019002094/osir-20181231.xml#1039483 Filing: 000155837019002094 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

53 filings · 2,505 latest values · 2,505 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001360886, 1360886, edgar:1360886

Also known as OSIRIS THERAPEUTICS, INC.

OSIRIS THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2018 2018-01-01 – 2018-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation